Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study
详细信息 查看全文
- 作者：Jun Fang1 ; Ran Zhang1 ; Huafang Wang ; Mei Hong ; Qiuling Wu ; Dimin Nie ; Yong You ; Zhaodong Zhong ; Weiming Li ; Yu Hu ; Linghui Xia ; xlh64@medmail.com.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：allo-HSCT ; allogeneic hematopoietic stem cell transplantation ; IDA ; idarubicin ; AML ; acute myeloid leukemia ; ALL ; acute lymphocytic leukemia ; OS ; overall survival ; DFS ; disease-free survival ; RR ; relapse rate ; BU ; busulfan ; CY ; cyclophosphamide ; VP-16 ; etoposide ; CR ; complete remission ; Ara-C ; cytarabine ; MLL ; mixed lineage leukemia ; PBSCs ; peripheral blood stem cells ; rhG-CSF ; recombinant human granulocyte colony-stimulating factor ; ANC ; absolute neutrophil count ; GVHD ; graft versus host diseas
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：46
- 期：Complete
- 页码：61-68
- 全文大小：1267 K
文摘
- •
We compared IDA-BUCY2 regimen for high-risk ALL versus AML undergoing allo-HSCT.
- •
IDA-BUCY2 regimen reduces relapse of high-risk AML undergoing allo-HSCT, but not ALL.
- •
IDA-BUCY2 regimen can improve survival of high-risk AML receiving allo-HSCT.